Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 18:13:1030398.
doi: 10.3389/fendo.2022.1030398. eCollection 2022.

Endocrine system involvement in patients with RASopathies: A case series

M A Siano  1 , R Pivonello  2 , M Salerno  3 , M Falco  1 , C Mauro  1 , D De Brasi  4 , A Klain  4 , S Sestito  5 , A De Luca  6 , V Pinna  6 , C Simeoli  2 , D Concolino  5 , Ciro Gabriele Mainolfi  7 , T Mannarino  7 , P Strisciuglio  3 , M Tartaglia  8 , D Melis  1   3
Affiliations

Endocrine system involvement in patients with RASopathies: A case series

M A Siano et al. Front Endocrinol (Lausanne). .

Abstract

Background and objectives: Endocrine complications have been described in patients affected by RASopathies but no systematic assessment has been reported. In this study, we investigate the prevalence of endocrine disorders in a consecutive unselected cohort of patients with RASopathies.

Study design: 72 patients with a genetically confirmed RASopathy (Noonan syndrome [NS], N=53; 29 LEOPARD syndrome [LS], N=2; cardiofaciocutaneous syndrome [CFCS], N=14; subjects showing co-occurring pathogenic variants in PTPN11 and NF1, N=3) and an age- and sex-matched healthy controls were included in the study. Endocrine system involvement was investigated by assessing the thyroid function, pubertal development, auxological parameters, adrenal function and bone metabolism.

Results: Short stature was detected in 40% and 64% of the NS and CFCS subcohorts, respectively. Patients showed lower Z-scores at DXA than controls (p<0.05) when considering the entire case load and both NS and CFCS groups. Vitamin D and Calcitonin levels were significantly lower (p< 0.01), Parathormone levels significantly higher (p<0.05) in patients compared to the control group (p<0.05). Patients with lower BMD showed reduced physical activity and joint pain. Finally, anti-TPO antibody levels were significantly higher in patients than in controls when considering the entire case load and both NS and CFCS groups.

Conclusions: The collected data demonstrate a high prevalence of thyroid autoimmunity, confirming an increased risk to develop autoimmune disorders both in NS and CFCS. Reduced BMD, probably associated to reduced physical activity and inflammatory cytokines, also occurs. These findings are expected to have implications for the follow-up and prevention of osteopenia/osteoporosis in both NS and CFCS.

Keywords: CFC; RASopathies; autoimmunity; bone mineral density; vitamin D.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. (2010) 1(1):2–26. doi: 10.1159/000276766 - DOI - PMC - PubMed
    1. Tidyman WE, Rauen KA. Expansion of the RASopathies. Curr Genet Med Rep (2016) 4(3):57–64. doi: 10.1007/s40142-016-0100-7 - DOI - PMC - PubMed
    1. Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab (2011) 25(1):161–79. doi: 10.1016/j.beem.2010.09.002 - DOI - PMC - PubMed
    1. Motta M, Pannone L, Pantaleoni F, Bocchinfuso G, Radio FC, Cecchetti S, et al. . Enhanced MAPK1 function causes a neurodevelopmental disorder within the RASopathy clinical spectrum. Am J Hum Genet (2020) 107(3):499–513. doi: 10.1016/j.ajhg.2020.06.018 - DOI - PMC - PubMed
    1. Rauen KA. The RASopathies. Annu Rev Genomics Hum Genet (2013) 14:355–69. doi: 10.1146/annurev-genom-091212-153523 - DOI - PMC - PubMed